Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: Pivotal role of metformin

International Journal of Clinical Practice

Volumn 64, Issue 2, 2010, Pages 149-159

  Al Maatouq, M ^a   Al Arouj, M ^b   Assaad, S H ^c   Assaad, S N ^c   Azar, S T ^d   Hassoun, A A K ^e   Jarrah, N ^f   Zatari, S ^g   Alberti, K G M M ^h  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Dasman Center for Research and Treatment of Diabetes   (Kuwait)

^c ALEXANDRIA UNIVERSITY   (Egypt)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^e Joslin Diabetes Center   (United Arab Emirates)

^f MUTAH UNIVERSITY   (Jordan)

^g AL HADA ARMED FORCES HOSPITAL   (Saudi Arabia)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FENOFIBRATE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 AGONIST; INCRETIN; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

BODY WEIGHT; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; CONFERENCE PAPER; CONSANGUINITY; DEVELOPING COUNTRY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DIET THERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EDEMA; FRACTURE; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GLUCOSE ABSORPTION; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE PLANNING; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IMMUNE DEFICIENCY; INSULIN RELEASE; KINESIOTHERAPY; LACTIC ACIDOSIS; LIFESTYLE; LOW DRUG DOSE; METABOLIC SYNDROME X; MIDDLE EAST; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PANCREAS ISLET BETA CELL; PANCREATITIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; UNITED KINGDOM; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGE DISTRIBUTION; AGED; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; MIDDLE EAST; PREVALENCE; YOUNG ADULT;

EID: 72449207580     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02235.x     Document Type: Conference Paper

References (75)

1. Clinical Guidelines Task Force, International Diabetes Federation. 2005 Global Guideline for Type 2 Diabetes. http://www.idf.org (accessed October 2009).
2. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009 32 : 193 203.
3. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 1972.
4. Al-Arouj M, Al-Magd M, Bougerra B et al. Recommendations for management of hyperglycaemia in Arab countries. Based on the consensus statement form the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Clin Diabetes (Middle East Edition) 2007 6 : 118 124.
5. Asian-Pacific Type 2 Diabetes Policy Group. Type 2 Diabetes: Practical Targets and Treatments, 4th edn. http://www.diabetes.com.au/pdf/Diabetes- TreatmentTargets-FINAL.pdf (accessed October 2009).
6. Latin American Diabetes Association (ALAD). Guidelines for the diagnosis, control and treatment of type 2 diabetes mellitus. Rev Assoc Lat Diab 2000 8 (Suppl. 1 101 167.
7. U.K. Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive diseases. Diabetes 1995 44 : 1249 1258.
8. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006 49 : 434 441.
9. International Diabetes Federation E-atlas of Diabetes, 2nd edn. http://www.eatlas.idf.org (accessed October 2009).
10. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY et al. Diabetes mellitus in Saudi Arabia. Saudi Med J 2004 25 : 1603 1610.
11. Malik M, Bakir A, Saab BA, King H. Glucose intolerance and associated factors in the multi-ethnic population of the United Arab Emirates: results of a national survey. Diabetes Res Clin Pract 2005 69 : 188 195.
12. Saadi H, Carruthers SG, Nagelkerke N et al. Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. Diabetes Res Clin Pract 2007 78 : 369 377.
13. Herman WH, Aubert RE, Engelgau MM et al. Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications. Diabet Med 1998 15 : 1045 1051.
14. World Health Organisation. Building the Knowledge Base on the Social Determinants of Health. Review of seven countries in the Eastern Mediterranean Region. 2008. WHO Regional Publications, Eastern Mediterranean Series 31. http://www.emro.who.int/dsaf/dsa939.pdf (accessed October 2009).
15. Karamanos B, Thanopoulou A, Angelico F et al. Nutritional habits in the Mediterranean Basin. The macronutrient composition of diet and its relation with the traditional Mediterranean diet. Multi-centre study of the Mediterranean Group for the Study of Diabetes (MGSD). Eur J Clin Nutr 2002 56 : 983 991.
16. Gray A, Raikou M, McGuire A et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000 320 : 1373 1378.
17. Clarke P, Gray A, Adler A et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001 44 : 298 304.
18. Al-Maatouq MA. Hospitalization patterns of diabetic patients: a six year experience at King Khalid University Hospital. Ann Saudi Med 1994 14 : 486 490.
19. The National Schools teach dangers of diabetes (press report). http://www.thenational.ae/article/20081111/NATIONAL/470858707/1020 (accessed October 2009).
20. Abdella N, Al Arouj M, Al Nakhi A, Al Assoussi A, Moussa M. Non-insulin-dependent diabetes in Kuwait: prevalence rates and associated risk factors. Diabetes Res Clin Pract 1998 42 : 187 196.
21. Ajlouni K, Jaddou H, Batieha A. Diabetes and impaired glucose tolerance in Jordan: prevalence and associated risk factors. J Intern Med 1998 244 : 317 323.
22. Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA et al. Obesity in Saudi Arabia. Saudi Med J 2005 26 : 824 829.
23. Al-Nozha M, Al-Khadra A, Arafah MR et al. Metabolic syndrome in Saudi Arabia. Saudi Med J 2005 26 : 1918 1925.
24. Azar S. A practical guideline for management of hypertension in patients with diabetes. J Med Liban 2000 48 : 392 395.
25. Al-Nozha MM, Abdullah M, Arafah MR et al. Hypertension in Saudi Arabia. Saudi Med J 2007 28 : 77 84.
26. Ibrahim MM. Epidemiology of hypertension in Egypt. Saudi J Kidney Dis Transpl 1999 10 : 352 356.
27. Ibrahim MM, Rizk H, Appel LJ. Hypertension prevalence, awareness, treatment, and control in Egypt. Results from the Egyptian National Hypertension Project (NHP). NHP Investigative Team. Hypertension 1995 26 : 886 890.
28. Habib SH. Frequency distribution of atherogenic dyslipidemia in Saudi type 2 diabetic patients. Pak J Physiol 2006 2 : 20 3.
29. Egyptian Hypertension Society. High density lipoprotein (hdl). http://www.ehs-egypt.net/nhp-lipoprotein.asp (accessed October 2009).
30. Akbar DH, Ahmed MM, Algamdi AA. Cardiovascular risk factors in Saudi Arabian and non-Saudi Arabian diabetic patients in Saudi Arabia. East Mediterr Health J 2003 9 : 884 892.
31. Akbar DH. Low rates of diabetic patients reaching good control targets. East Mediterr Health J 2001 7 : 671 678.
32. Mubarak FM, Froelicher ES, Jaddou HY, Ajlouni KM. Hypertension among 1000 patients with type 2 diabetes attending a national diabetes center in Jordan. Ann Saudi Med 2008 28 : 346 351.
33. Badr KF, Boudia KM, Alami M et al. Physician assessment of stroke risk in hypertensive patients in the Middle East and Africa: results of the action survey. Ethn Dis 2007 17 : 274 279.
34. Abchee A, Puzantian H, Azar ST et al. Predictors of coronary artery disease in the Lebanese population. Thromb Res 2006 117 : 631 637.
35. Alwakeel JS, Sulimani R, Al-Asaad H et al. Diabetes complications in 1952 type 2 diabetes mellitus patients managed in a single institution in Saudi Arabia. Ann Saudi Med 2008 28 : 260 266.
36. AlKharji F, Alshemmeri N, Mehrabi L, Hafez M, Fakher O. Prevalence and risk factors for diabetic retinopathy among kuwaiti diabetics. Kuwait Med J 2006 38 : 203 206.
37. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
38. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007 370 : 1687 1697.
39. Shaheen FA, Al-Khader AA. Preventive strategies of renal failure in the Arab world. Kidney Int Suppl 2005 98 : S37 40.
40. Akbar DH, Mira SA, Zawawi TH, Malibary HM. Subclinical diabetic neuropathy: a common complication in Saudi diabetics. Saudi Med J 2000 21 : 433 437.
41. Azab AS. Glycemic control among diabetic patients. Saudi Med J 2001 22 : 407 409.
42. Osman AK, al-Nozha MM. Risk factors of coronary artery disease in different regions of Saudi Arabia. East Mediterr Health J 2000 6 : 465 474.
43. Taha AZ, Bella H. Heart disease risk factors: prevalence and knowledge in a primary care setting, Saudi Arabia. East Mediterr Health J 1998 4 : 293 300.
44. Bailey CJ, Campbell IW, Chan JCN, Davidson JA, Howlett HCS, Ritz P (eds). Metformin: The Gold Standard. A Scientific Handbook. Chichester : John Wiley & Sons, 2007.
45. Lindsay JR, Duffy NA, McKillop AM et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 2005 22 : 654 657.
46. Yasuda N, Inoue T, Nagakura T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002 298 : 779 784.
47. Golay A. Metformin and body weight. Int J Obes (Lond) 2008 32 : 61 72.
48. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007 147 : 386 399.
49. ® SR) in individuals intolerant to standard metformin - results from four UK centres. Br J Diabetes Vasc Dis 2007 7 : 225 228.
50. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006 25 : CD002967.
51. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005 28 : 539 543.
52. Monami M, Marchionni N, Mannucci E. Winners and losers at the rosiglitazone gamble. A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. Diabetes Res Clin Pract 2008 82 : 48 57.
53. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 : 2457 2471. (Pubitemid 46919772)
54. Home PD, Pocock SJ, Beck-Nielsen H. Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis. Evid Based Med 2007 12 : 170.
55. Lindberg M, Astrup A. The role of glitazones in management of type 2 diabetes. A dream or a nightmare? Obes Rev 2007 8 : 381 384.
56. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008 2 : CD006739.
57. European Medicines Agency. Scientific Discussion (Vildagliptin). http://www.emea.europa.eu/humandocs/PDFs/EPAR/eucreas/H-807-en6.pdf (accessed October 2009).
58. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 865
59. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 1577 1589.
60. Kooy A, de Jager J, Lehert P et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009 169 : 616 625.
61. Kao J, Tobis J, McClelland RL et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004 93 : 1347 1350.
62. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005 366 : 1279 1289.
63. Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitazone clinical trial in macrovascular events 04). Stroke 2007 38 : 865 873.
64. Erdmann E, Dormandy JA, Charbonnel B et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007 49 : 1772 1780.
65. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004 25 : 10 6.
66. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007 1 : CD005166.
67. Motta DA. Metformin in the treatment of polycystic ovary syndrome. Curr Pharm Des 2008 14 : 2121 2125.
68. Mallewa JE, Wilkins E, Vilar J et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother 2008 62 : 648 660.
69. Baptista T, ElFakih Y, Uzcátegui E et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008 22 : 477 495.
70. Musi N, Hirshman MF, Nygren J et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002 1 : 2074 2081.
71. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005 330 : 1304 1305.
72. Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol 2009 113 : 193 205.
73. Clinical Guidelines Task Force, International Diabetes Federation. 2007. Guideline for Management of Postmeal Glucose. http://www.idf.org (accessed October 2009).
74. Al-Arouj M, Bouguerra R, Buse J et al. Recommendations for management of diabetes during Ramadan. Diabetes Care 2005 28 : 2305 2311.
75. Kobeissy A, Zantout MS, Azar ST. Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan. Clin Ther 2008 30 : 1408 1415.